{"id":{"repo_id":"purdue-thes","oai_identifier":"oai:docs.lib.purdue.edu:open_access_dissertations-2369"},"canonical_url":"https://search.dev.ndltd.org/etd/purdue-thes/oai:docs.lib.purdue.edu:open_access_dissertations-2369","repository":{"repo_id":"purdue-thes","name":"Purdue University","base_url":"https://docs.lib.purdue.edu/do/oai/"},"display":{"title":"A General Purpose Programmable Microfluidic Platform for Screening and Optimization of Biological Assays","abstract":"Screening is a fundamental process in today’s medicine and clinical diagnostics, comprising of several processes ranging from finding new target molecules having the desired therapeutic potential to identifying biomarkers for accurate diagnosis of a spectrum of diseases. Current high throughput screening (HTS) platforms leverage sophisticated robotics to perform a large number of experiments very quickly, an otherwise unmanageable task with manual labor. However, these systems are capital intensive which limit their use to large pharmaceutical companies or larger research labs. Additionally, reagent consumption is of the order of 10-100 µL per assay, which leads to substantial consumables cost. Recently proposed droplet microfluidic technologies have the potential to substantially reduce assay costs by performing reactions using nanoliter volumes at very rapid rates. However, their incorporation into screening workflows is limited owing to various technological challenges such as on-chip droplet storage for long incubation assays, fluid waste due to large dead volumes, lack of programmable control over individual assay droplets, etc.","abstract_html":"Screening is a fundamental process in today’s medicine and clinical diagnostics, comprising of several processes ranging from finding new target molecules having the desired therapeutic potential to identifying biomarkers for accurate diagnosis of a spectrum of diseases. Current high throughput screening (HTS) platforms leverage sophisticated robotics to perform a large number of experiments very quickly, an otherwise unmanageable task with manual labor. However, these systems are capital intensive which limit their use to large pharmaceutical companies or larger research labs. Additionally, reagent consumption is of the order of 10-100 µL per assay, which leads to substantial consumables cost. Recently proposed droplet microfluidic technologies have the potential to substantially reduce assay costs by performing reactions using nanoliter volumes at very rapid rates. However, their incorporation into screening workflows is limited owing to various technological challenges such as on-chip droplet storage for long incubation assays, fluid waste due to large dead volumes, lack of programmable control over individual assay droplets, etc.","abstract_has_math":false,"creators":["Thakur, Raviraj"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Mechanical Engineering","degree_department":null,"school":null,"contributors":["Steven T Wereley","Cagri A Savran","Nicole L Key","T.N. Vijaykumar"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-01-01T08:00:00Z","date_published":"2015-01-01T08:00:00Z","updated_at":"2026-07-24T03:54:25Z","subjects":["Droplet microfluidics","Lab-on-chip","Microfluidics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://docs.lib.purdue.edu/open_access_dissertations/1153","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Steven T Wereley","Cagri A Savran","Nicole L Key","T.N. Vijaykumar"]},{"key":"dc:creator","label":"Author","values":["Thakur, Raviraj"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Mechanical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Droplet microfluidics","Lab-on-chip","Microfluidics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://docs.lib.purdue.edu/open_access_dissertations/1153"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Screening is a fundamental process in today’s medicine and clinical diagnostics, comprising of several processes ranging from finding new target molecules having the desired therapeutic potential to identifying biomarkers for accurate diagnosis of a spectrum of diseases. Current high throughput screening (HTS) platforms leverage sophisticated robotics to perform a large number of experiments very quickly, an otherwise unmanageable task with manual labor. However, these systems are capital intensive which limit their use to large pharmaceutical companies or larger research labs. Additionally, reagent consumption is of the order of 10-100 µL per assay, which leads to substantial consumables cost. Recently proposed droplet microfluidic technologies have the potential to substantially reduce assay costs by performing reactions using nanoliter volumes at very rapid rates. However, their incorporation into screening workflows is limited owing to various technological challenges such as on-chip droplet storage for long incubation assays, fluid waste due to large dead volumes, lack of programmable control over individual assay droplets, etc."]},{"key":"dc:title","label":"Title","values":["A General Purpose Programmable Microfluidic Platform for Screening and Optimization of Biological Assays"]}]}],"canonical_facts":{"dc:contributor":["Steven T Wereley","Cagri A Savran","Nicole L Key","T.N. Vijaykumar"],"dc:creator":["Thakur, Raviraj"],"dc:description.abstract":["Screening is a fundamental process in today’s medicine and clinical diagnostics, comprising of several processes ranging from finding new target molecules having the desired therapeutic potential to identifying biomarkers for accurate diagnosis of a spectrum of diseases. Current high throughput screening (HTS) platforms leverage sophisticated robotics to perform a large number of experiments very quickly, an otherwise unmanageable task with manual labor. However, these systems are capital intensive which limit their use to large pharmaceutical companies or larger research labs. Additionally, reagent consumption is of the order of 10-100 µL per assay, which leads to substantial consumables cost. Recently proposed droplet microfluidic technologies have the potential to substantially reduce assay costs by performing reactions using nanoliter volumes at very rapid rates. However, their incorporation into screening workflows is limited owing to various technological challenges such as on-chip droplet storage for long incubation assays, fluid waste due to large dead volumes, lack of programmable control over individual assay droplets, etc."],"dc:identifier":["https://docs.lib.purdue.edu/open_access_dissertations/1153"],"dc:subject":["Droplet microfluidics","Lab-on-chip","Microfluidics"],"dc:title":["A General Purpose Programmable Microfluidic Platform for Screening and Optimization of Biological Assays"],"thesis:degree_discipline":["Mechanical Engineering"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T03:54:25Z"}